Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

@article{akkus2026prognostic,
  title = {{Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)}},
  author = {Aysun Fatma Akkuş and Hatice Bölek and Esma Kaplan Tüzün and Elif Serteşen Camöz and Safa Can Efil and Murad Guliyev and Selver Işık and Caner Kapar and Serhat Sekmek and Halil Göksel Güzel and Sercan Ön and Sema Sezin Göksu and Özlem Nuray Sever and Çagatay Arslan and Nuri Karadurmuş and Musfafa Özgüroğlu and Mehmet Ali Nahit Sendur and Deniz Tural and Muhammet Bekir Hacıoğlu and Emre Yekedüz and Yüksel Ürün},
  journal = {BMC Cancer},
  year = {2026},
  month = aug,
  doi = {10.1186/s12885-026-16664-1},
  url = {https://doi.org/10.1186/s12885-026-16664-1},
  note = {CC BY-NC-ND 4.0},
}

TY  - JOUR
TI  - Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)
AU  - Aysun Fatma Akkuş
AU  - Hatice Bölek
AU  - Esma Kaplan Tüzün
AU  - Elif Serteşen Camöz
AU  - Safa Can Efil
AU  - Murad Guliyev
AU  - Selver Işık
AU  - Caner Kapar
AU  - Serhat Sekmek
AU  - Halil Göksel Güzel
AU  - Sercan Ön
AU  - Sema Sezin Göksu
AU  - Özlem Nuray Sever
AU  - Çagatay Arslan
AU  - Nuri Karadurmuş
AU  - Musfafa Özgüroğlu
AU  - Mehmet Ali Nahit Sendur
AU  - Deniz Tural
AU  - Muhammet Bekir Hacıoğlu
AU  - Emre Yekedüz
AU  - Yüksel Ürün
PY  - 2026
DA  - 2026/08/06
JO  - BMC Cancer
DO  - 10.1186/s12885-026-16664-1
UR  - https://doi.org/10.1186/s12885-026-16664-1
AB  - Background: Immune checkpoint inhibitor (ICI)-based combination therapies are widely used as first-line treatment for metastatic renal cell carcinoma (mRCC); however, considerable variability in clinical outcomes persists. Therefore, the identification of reliable and easily applicable prognostic markers remains of significant clinical importance. This study aimed to evaluate the prognostic value of the Gustave Roussy Immune (GRIm) score in patients with mRCC treated with first-line ICI-based combination regimens.  Materials and methods: In this retrospective, multicenter cohort study, patients with mRCC who received first-line ICI-based combination therapy were identified from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. The GRIm score was calculated using pretreatment serum lactate dehydrogenase, serum albumin, and neutrophil-to-lymphocyte ratio. Patients were categorized into low (0–1) and high (2–3) GRIm score groups. The primary endpoints were time to treatment failure (TTF) and overall survival (OS).  Results: A total of 78 patients were included, of whom 14 (17.9%) were classified in the high GRIm score group and 64 (82.1%) in the low GRIm score group. Patients with a high GRIm score had significantly shorter TTF and OS compared with those in the low GRIm score group (TTF: 5.8 vs. 11.0 months, p = 0.017; OS: 9.3 vs. 36.0 months, p = 0.001). The combined IMDC and GRIm model showed a modest numerical improvement in discrimination for OS compared with either model alone.  Conclusions: The GRIm score is significantly associated with survival outcomes in patients with mRCC treated with first-line ICI-based combination therapies. Given its simplicity and reliance on routinely available clinical parameters, the GRIm score may serve as a practical and accessible adjunct to existing prognostic models in clinical practice.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12885-026-16664-1.
SN  - 1471-2407
ER  -